Advertisement
These restated quarterly reports also correct an error related to the USGAAP valuation of certain stock-based compensation plans identified during theyear-end audit. The valuation was included in the 'Canadian to US GAAP'reconciliation to the financial statements in previously filed 2007 MDSquarterly reports. These stock-based compensation plans were correctly valuedunder Canadian GAAP and in MDS' 2007 annual financial statements in US GAAP.
Advertisement
The restated quarterly reports are available in the "For Investors"section of the MDS website at www.mdsinc.com.
To assist investors with understanding the impact of MDS' conversion fromCanadian to US GAAP, both an "MDS US GAAP Primer", which provides an overviewof the relevant differences between US and Canadian GAAP affecting MDS, andreconciliation tables for MDS and its business units are also available on theMDS website at www.mdsinc.com.
About MDS Inc.
MDS Inc. is a global life sciences company that provides market-leadingproducts and services that our customers need for the development of drugs andthe diagnosis and treatment of disease. We are a leading global provider ofpharmaceutical contract research, medical isotopes for molecular imaging,radiotherapeutics, and analytical instruments. MDS has more than 5,500 highlyskilled people in 29 countries. Find out more at www.mdsinc.com or by calling1-888-MDS-7222, 24 hours a day.
SOURCE MDS Inc.
